RxDoctor Payments Data

Mark Petrizzi, MD

Family Medicine · Henrico, VANPI 1336152511

Payments from drug & device makers

$1,638in general payments, 2019–2025

Across 82 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$363
  • AbbVie$316
  • Lilly USA, LLC$246
  • Amgen$135
  • Novartis$122
  • Pfizer$93
  • plus $364 from 11 others

What the payments were for

  • Food & beverage$1,61999%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,638 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$84,025
Medicare patients
150
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$34,320
MounjaroTirzepatide24$33,812
EliquisApixaban31$29,321
Xtampza ErOxycodone Myristate11$26,555
JanuviaSitagliptin Phosphate17$20,005
MyrbetriqMirabegron19$12,151
Repatha SureclickEvolocumab12$9,787
SymbicortBudesonide/Formoterol Fumarate16$6,310
Lagevrio (Eua)Molnupiravir11$4,135
Fentanyl12$3,112
Aripiprazole30$2,186
SynthroidLevothyroxine Sodium12$1,609
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,366
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen67$1,315
AsmanexMometasone Furoate11$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$363$34,32019 claims
Lilly USA, LLCMounjaro$246$33,81224 claims
PfizerEliquis$93$29,32131 claims
AstraZenecaSymbicort$92$6,31016 claims
AbbVieSynthroid$316$1,60912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Henrico

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →